This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Tao Pei, Ph.D.
Senior Vice President, Chemistry at Arrowhead Pharmaceuticals
Speaker

Profile


Dr. Tao Pei is the Senior VP of Discovery Chemistry at Arrowhead Pharmaceuticals. In this role, he leads multiple function groups in the exploration and development of TRiM™ platforms to several extrahepatic tissues including lung, skeletal muscle, adipose, and CNS. Tao is a key architect of Arrowhead’s TRiM™ technology and contributor to the final design of Arrowhead’s first TRiM™ candidate, Olpasiran—now in Phase III clinical trials.

Prior to Arrowhead, Tao was at Merck Process Research and Merck Sirna. There, he contributed to the final API chemistry of Merck’s Grazoprevir which has been approved to treat Hepatitis C.

Tao earned his PhD in chemistry from Duke University where he performed research in Dr. Ross Widenhoefer’s lab.

Agenda Sessions

  • Novel TRiM™ Platform for Delivery of RNAi Therapeutics to Adipose Tissue

    9:00am